Search Results - Kasiborski, F

  • Showing 1 - 3 results of 3
Refine Results
  1. 1
    P3-14-13: A Prospective Open-Label Randomized Phase II Neoadjuvant Study of Non-Pegylated Liposomal Doxorubicin (MYOCET®) Plus Cyclophosphamide and Trastuzumab Versus Conventional Doxorubicin Plus Cyclophosphamide Alone, Each Followed by Docetaxel and Trastuzumab, in HER2−Positive Breast Cancer Patients

    P3-14-13: A Prospective Open-Label Randomized Phase II Neoadjuvant Study of Non-Pegylated Liposomal Doxorubicin (MYOCET®) Plus Cyclophosphamide and Trastuzumab Versus Conventional... by Llombart-Cussac, A, Pernas-Simon, S, Rezai, M, Hauschild, M, Venturini, M, Machiels, J-P, Paepke, S, Luporsi, E, Kasiborski, F, Kayitalire, L

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:
  2. 2
    A dose-finding and pharmacokinetic study of I.V. vinflunine in combination with doxorubicin as first line treatment of metastatic breast cancer

    A dose-finding and pharmacokinetic study of I.V. vinflunine in combination with doxorubicin as first line treatment of metastatic breast cancer by Machiels, J, Chollet, P, Taleb, A, Baurain, J, Humblet, Y, Mazzeo, F, Zaman, K, Kasiborski, F, Bauer, J

    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    A MULTICENTRIC PHASE II RANDOMISED STUDY OF ORAL VINORELBINE (VRL) PLUS HYDROCORTISONE (HC) AND INTRAVENOUS (IV) VRL PLUS HC AS FIRST-LINE CHEMOTHERAPY OF METASTATIC ANDROGEN-INDEPENDENT PROSTATE CANCER (AIPC)

    A MULTICENTRIC PHASE II RANDOMISED STUDY OF ORAL VINORELBINE (VRL) PLUS HYDROCORTISONE (HC) AND INTRAVENOUS (IV) VRL PLUS HC AS FIRST-LINE CHEMOTHERAPY OF METASTATIC ANDROGEN-INDEP... by Demkow, T, Kliment, J, Caty, A, Lesaunier, F, Abratt, R, Kasiborski, F, Brandely, M, Culine, S

    Get full text
    Items that cite this one
    Article
    Save to List
    Saved in:

Search Tools: